P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.

Auteurs : Najem A, Krayem M, Sales F, Hussein N, Badran B, Robert C, Awada A, Journe F, Ghanem G
Année : 2017
Journal : Eur J Cancer
Volume : 83
Pages : 154-165